Your session is about to expire
← Back to Search
Rucaparib + Nivolumab for Leiomyosarcoma
Study Summary
This trial is testing whether combining two drugs, rucaparib and nivolumab, may be effective in treating leiomyosarcoma (LMS), a type of cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 564 Patients • NCT01968213Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My liver function tests are within the required range.My LMS cannot be removed by surgery and has spread.I finished any cancer treatments at least 3 weeks ago, and my side effects are mild.I can take care of myself and perform daily activities.I finished my radiation therapy at least 2 weeks ago.I do not have any other cancer that needs treatment or could affect this trial.I am 18 years old or older.I have a weakened immune system due to conditions like HIV, Hepatitis B/C, or autoimmune diseases.You have had an allergic reaction to any ingredient in the study drug.I can provide tissue samples for study, either a block or 20 slides.My blood, kidney functions, and blood cell counts are within the required ranges.I have had a stem cell or organ transplant in the past.I have had 1 to 3 treatments for my LMS, or I declined the first standard treatment.I am not pregnant, willing to use birth control during and 6 months after the study, and will not breastfeed.I do not have any severe illnesses or recent major heart issues, and if I have brain metastases, they are stable without recent treatment changes.I have recovered from previous treatment side effects, except for hair loss or stable nerve pain.My cancer can be measured and has grown in previously treated areas.I have a stomach or intestine condition that affects how my body absorbs medication.I have never been treated with PARP inhibitors or PD-1/PD-L1 antibodies.I have lung inflammation not caused by an infection.I am not pregnant or breastfeeding.I am willing to have a biopsy if my doctor thinks it's safe.
- Group 1: Rucaparib in combination with Nivolumab
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there still room for more people in this trial?
"Although this specific trial is no longer looking for participants, 817 other clinical trials are. This particular study was first posted on November 5th 2020 and updated last on September 6th 2022 according to the website clinicaltrials.gov"
What are the approved uses for Rucaparib?
"Rucaparib is frequently used to help patients with malignant neoplasms, but it can also be given as treatment for other diseases such as unresectable melanoma, squamous cell carcinoma, and metastatic esophageal adenocarcinoma."
How many different facilities are coordinating this clinical trial?
"So far, 8 clinical trial sites are running this protocol, including Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) in Basking Ridge, Memorial Sloan Kettering Nassau (Limited Protocol Activities) in Uniondale, and Memorial Sloan Kettering Bergen (Limited Protocol Activities) in Montvale."
How many patients are included in this clinical trial?
"As of September 6th, 2022, this study is no longer admitting patients. The trial was first posted on 11/5/2020. If you are interested in other clinical trials, there are 773 studies for Rucaparib and 44 leiomyosarcoma trials that are still recruiting participants."
What is the official government stance on Rucaparib?
"While there is some clinical evidence supporting the safety of Rucaparib, it only received a 2 because Phase 2 trials lack data regarding efficacy."
Can you please tell me what studies have been done using Rucaparib in the past?
"At present, there are 773 clinical trials underway for Rucaparib. 88 of those live studies are in Phase 3. While the majority of trials for Rucaparib are based in Columbus, Ohio, there are 42175 locations running studies for this treatment."
What makes this clinical trial unique?
"Rucaparib has been under clinical study for a decade. The first official research project occurred in 2010 and was funded by Medarex. After the initial 127-person Phase 1 trial, Rucaparib received drug approval. Currently, there are 773 active trials involving this medication taking place in 2398 cities and 50 countries around the world."
Share this study with friends
Copy Link
Messenger